Remove 2021 Remove Vaccine Remove Virus
article thumbnail

mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit

The Pharma Data

This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. mRNA Technology Transfer Programme Moves Into Phase 2.0, 2026–2030).

Vaccine 40
article thumbnail

Olgotrelvir 

New Drug Approvals

By binding to the active site of the protease, the drug prevents this cleavage process, effectively halting viral assembly and impeding the virus’s ability to produce future virions. [1] “Second Generation Oral Mpro Inhibitor for COVID-19 Treatment Proceeds in Phase 3 Study” Precision Vaccinations. 5 (1): 42–61.e23.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Levers for Biological Progress

Codon

Such models will, in turn, make it much easier to invent the sorts of platform tools that Amodei asserts “drive >50% of progress in biology,” such as CRISPR and mRNA vaccines, because the creation of these tools ultimately derive from a deeper understanding of how cells work. The cost of sequencing a human genome.

DNA 132
article thumbnail

WHO Scientific Group Publishes Findings on COVID-19’s Origins

The Pharma Data

The group, made up of virologists, epidemiologists, public health professionals, and biosafety specialists, has been working for over three years to shed light on one of the most pressing questions in modern global health: how did SARS-CoV-2, the virus responsible for COVID-19, first infect humans?

article thumbnail

Moderna says its COVID-19 vaccine shows promise in elderly patients

The Pharma Data

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Each patient was given two 100 microgram doses of the vaccine 28 days apart. These antibodies were higher than those seen in people who had recovered from the virus.

Vaccine 90
article thumbnail

Coronavirus vaccine: UK signs deals for 90 million virus vaccine doses

The Pharma Data

The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. It means the UK has placed orders for six experimental vaccines, taking its potential stockpile to 340 million doses.

Vaccine 52
article thumbnail

Moderna to Build mRNA Vaccine Portfolio Following COVID-19 Success | 2021-01-11

The Pharma Data

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. based company has been in business for 10 years, but the COVID-19 vaccine was its first approved product. 18, 2020 ). It has already received $2.8

Vaccine 52